Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a
maximum of 30 days followed by a 26-week treatment period. Lab assessments will be completed
throughout the study along with PRO assessments.